Publication | Open Access

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Catnon TrialTreatment StrategiesRadiation TherapyGliomaMedicineClinical TrialsInterim ResultsNeurologyHigh-grade GliomasCancer TreatmentOncologyRadiation OncologyCancer ResearchMolecular OncologyPhase 3Health Sciences